The earnings call reflects a mixed sentiment. The successful launch and initial performance of GRAFAPEX, along with strong financial discipline and cash position, are significant positives. However, decreases in net revenue, negative net income for the quarter, and challenges like Rupall's generic competition present notable concerns. The focus on GRAFAPEX's strong launch suggests optimism, but is tempered by current declines in other areas.

Company Guidance -

Q4 2025

During the Medexus Pharmaceuticals Fourth Quarter and Fiscal Year-End 2025 Conference Call, the company provided detailed financial guidance, emphasizing the successful commercialization of GRAFAPEX, the brand name for treosulfan, in the U.S. Medexus reported $0.6 million in product-level revenue for GRAFAPEX in fiscal Q4 '25 and over $2.5 million in fiscal Q1 '26, with expectations for it to be accretive to quarterly operating cash flows by fiscal Q4 '26. The company's fiscal Q4 net revenue was $24.8 million, down from $26 million the previous year, primarily due to $2.7 million in GRAFAPEX-related investments. Adjusted EBITDA for fiscal Q4 '25 was $2.3 million, a decrease from $4.4 million last year, but fiscal year '25 saw a record adjusted EBITDA of $20.2 million, up from $19.5 million in fiscal '24. The company also reported a net income of $2.2 million for fiscal year '25, a significant improvement from the negative $0.2 million in fiscal '24. Other product updates included a 70% growth in Trecondyv unit demand in Canada and a 1% increase for IXINITY in the U.S. Medexus outlined plans for GRAFAPEX's continued integration into healthcare facilities, with 34 of 180 transplant centers already ordering the product, and highlighted a strong market response with positive formulary inclusion from multiple commercial players.

Successful Launch of GRAFAPEX

Medexus achieved $0.6 million of product level revenue for GRAFAPEX in fiscal Q4 '25 and preliminary estimates indicate over $2.5 million in fiscal Q1 '26, showing strong initial market uptake.

Strong Financial Discipline

Record adjusted EBITDA of $20.2 million and record net income of $2.2 million for fiscal year '25, primarily due to ongoing financial discipline.

Positive Market Response to Treosulfan

Treosulfan's market exclusivity in Canada led to a 70% growth in unit demand over the trailing 12-month period ending March 31, 2025.

Cash Position Improvement

Cash on hand increased to $24 million at March 31, 2025, compared to $5.3 million at March 31, 2024, due to a public offering and strong operating cash flow.

Adjusted EBITDA Growth

Fiscal year '25 adjusted EBITDA of $20.2 million, up from $19.5 million in fiscal year '24.

Medexus Pharmaceuticals Inc (TSE:MDP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:MDP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2025	2026 (Q1)	- / -	―	―	―	―
Jun 25, 2025	2025 (Q4)	-0.09 / -0.03	0.043	-164.52% (-0.07)	―	―
Feb 05, 2025	2025 (Q3)	0.05 / 0.04	-0.027	250.00% (+0.07)	―	―
Nov 07, 2024	2025 (Q2)	0.03 / 0.00	-0.069	―	―	―
Aug 07, 2024	2025 (Q1)	0.07 / 0.11	0.041	166.67% (+0.07)	―	―
Jun 25, 2024	2024 (Q4)	-0.02 / 0.04	0.466	-90.88% (-0.42)	―	―
Feb 07, 2024	2024 (Q3)	0.08 / -0.03	-0.096	71.43% (+0.07)	―	―
Nov 08, 2023	2024 (Q2)	0.00 / -0.07	-0.192	64.29% (+0.12)	―	―
Aug 09, 2023	2024 (Q1)	0.01 / 0.04	-0.096	142.86% (+0.14)	―	―
Jun 21, 2023	2023 (Q4)	-0.06 / 0.47	-0.37	225.93% (+0.84)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:MDP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jun 25, 2025	C$3.35	C$3.15	-5.97%
Feb 05, 2025	C$3.79	C$3.05	-19.53%
Nov 07, 2024	C$2.20	C$2.17	-1.36%
Aug 07, 2024	C$2.27	C$2.46	+8.37%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Medexus Pharmaceuticals Inc (TSE:MDP) report earnings?

Medexus Pharmaceuticals Inc (TSE:MDP) is schdueled to report earning on Aug 06, 2025, Before Open (Confirmed).

What is Medexus Pharmaceuticals Inc (TSE:MDP) earnings time?

Medexus Pharmaceuticals Inc (TSE:MDP) earnings time is at Aug 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:MDP EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing